Shanghai Henlius Biotech Inc. (HKG: 2696) announced that its biosimilar of Roche’s Avastin (bevacizumab), Hanbeitai, has received marketing approval in Bolivia. This marks the first approval for the drug outside of China. The product will be marketed under the trade name Longiva in the Latin American country.
Licensing Deal
Henlius entered into a licensing agreement with Eurofarma Laboratorios S.A. in 2022, granting the Brazilian firm exclusive development, manufacturing, and commercialization rights to its Hanlikang (rituximab biosimilar), Hanquyou (trastuzumab), and Hanbeitai. These products have now all been approved in Bolivia and other Latin American countries.-Fineline Info & Tech
